株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

Lipicard Technologies Limited:製品パイプライン分析

Lipicard Technologies Limited - Product Pipeline Review - 2016

発行 Global Markets Direct 商品コード 306628
出版日 ページ情報 英文 58 Pages
即納可能
価格
本日の銀行送金レート: 1USD=115.18円で換算しております。

2016年12月31日まで 年末キャンペーン割引: Global Markets Direct社発行レポート
ご注意: ショッピングカートでは適用されませんので、割引価格についてはお問い合わせください

Back to Top
Lipicard Technologies Limited:製品パイプライン分析 Lipicard Technologies Limited - Product Pipeline Review - 2016
出版日: 2016年07月30日 ページ情報: 英文 58 Pages
概要

当レポートでは、Lipicard Technologies Limitedにおける治療薬開発パイプラインの現況と各開発段階の比較分析、薬剤標的、作用機序、投与経路、分子タイプ別の治療薬の評価、最新の企業ニュースや発表、後期段階および中止されたプロジェクトに関する情報などを提供しています。

Lipicard Technologies Limitedの基本情報

Lipicard Technologies Limitedの概要

  • 主要情報
  • 企業情報

Lipicard Technologies Limited:R&Dの概要

  • 主な治療範囲

Lipicard Technologies Limited:パイプラインのレビュー

  • 開発段階別のパイプライン製品
  • 単剤製品

Lipicard Technologies Limited:パイプライン製品の概況

  • 初期段階にあるパイプライン製品
    • 前臨床段階にある製品/併用療法モダリティ

Lipicard Technologies Limited:薬剤プロファイル

  • Gabafol
  • KeraKlear
  • LT-1121
  • LT-1123
  • LT-2121
  • LT-2221
  • LT-2223
  • LT-2321
  • LT-2322
  • LT-2323
  • LT-2421
  • LT-2423
  • LT-2521
  • LT-3121
  • LT-3122
  • LT-4121
  • LT-4122
  • LT-4123
  • LT-4124
  • LT-4125
  • LT-4126
  • LT-5121
  • LT-5122
  • LT-5221
  • LT-5222
  • LT-5223
  • LT-5321
  • LT-5322
  • LT-5323
  • LT-5421
  • LT-5423
  • LT-6121
  • Peroxibrate
  • Platrol
  • Raviprofen

Lipicard Technologies Limited:パイプライン分析

  • 標的別
  • 投与経路別
  • 分子タイプ別
  • 作用機序別

Lipicard Technologies Limited:休止中のプロジェクト

Lipicard Technologies Limited:本社と子会社の所在地

付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC08105CDB

Summary

Global Markets Direct's, 'Lipicard Technologies Limited - Product Pipeline Review - 2016', provides an overview of the Lipicard Technologies Limited's pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Lipicard Technologies Limited, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the pipeline therapeutic landscape of Lipicard Technologies Limited
  • The report provides overview of Lipicard Technologies Limited including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses Lipicard Technologies Limited's pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features Lipicard Technologies Limited's out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

  • Evaluate Lipicard Technologies Limited's strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Lipicard Technologies Limited
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Lipicard Technologies Limited's pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Lipicard Technologies Limited Snapshot
    • Lipicard Technologies Limited Overview
    • Key Information
    • Key Facts
  • Lipicard Technologies Limited - Research and Development Overview
    • Key Therapeutic Areas
  • Lipicard Technologies Limited - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • Lipicard Technologies Limited - Pipeline Products Glance
    • Lipicard Technologies Limited - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • Lipicard Technologies Limited - Drug Profiles
    • gabafol
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • KeraKlear
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • LT-1121
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • LT-1123
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • LT-2121
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • LT-2221
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • LT-2223
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • LT-2321
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • LT-2322
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • LT-2323
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • LT-2421
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • LT-2423
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • LT-2521
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • LT-3121
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • LT-3122
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • LT-4121
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • LT-4122
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • LT-4123
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • LT-4124
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • LT-4125
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • LT-4126
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • LT-5121
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • LT-5122
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • LT-5221
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • LT-5222
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • LT-5223
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • LT-5321
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • LT-5322
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • LT-5323
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • LT-5421
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • LT-5423
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • LT-5521
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • peroxibrate
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • platrol
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • raviprofen
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • LT-6121
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Lipicard Technologies Limited - Pipeline Analysis
  • Lipicard Technologies Limited - Pipeline Products by Target
  • Lipicard Technologies Limited - Pipeline Products by Route of Administration
  • Lipicard Technologies Limited - Pipeline Products by Molecule Type
  • Lipicard Technologies Limited - Pipeline Products by Mechanism of Action
  • Lipicard Technologies Limited - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Lipicard Technologies Limited, Key Information
  • Lipicard Technologies Limited, Key Facts
  • Lipicard Technologies Limited - Pipeline by Indication, 2016
  • Lipicard Technologies Limited - Pipeline by Stage of Development, 2016
  • Lipicard Technologies Limited - Monotherapy Products in Pipeline, 2016
  • Lipicard Technologies Limited - Preclinical, 2016
  • Lipicard Technologies Limited - Discovery, 2016
  • Lipicard Technologies Limited - Pipeline by Target, 2016
  • Lipicard Technologies Limited - Pipeline by Route of Administration, 2016
  • Lipicard Technologies Limited - Pipeline by Molecule Type, 2016
  • Lipicard Technologies Limited - Pipeline Products by Mechanism of Action, 2016

List of Figures

  • Lipicard Technologies Limited - Pipeline by Top 10 Indication, 2016
  • Lipicard Technologies Limited - Pipeline by Stage of Development, 2016
  • Lipicard Technologies Limited - Monotherapy Products in Pipeline, 2016
  • Lipicard Technologies Limited - Pipeline by Target, 2016
  • Lipicard Technologies Limited - Pipeline by Route of Administration, 2016
  • Lipicard Technologies Limited - Pipeline by Molecule Type, 2016
  • Lipicard Technologies Limited - Pipeline Products by Mechanism of Action, 2016
Back to Top